GLUE

Monte Rosa Therapeutics Stock Analysis

AI Rating

Great
  • Quality9/10
  • Growth↑ 8/10
  • Momentum↑ 9/10
Monte Rosa Therapeutics sales and earnings growth
GLUE Growth
Good
  • Revenue Y/Y↑ 1112.27%
  • EPS Y/Y↑ 117.58%
  • FCF Y/Y↑ 330.98%
Monte Rosa Therapeutics gross and profit margin trends
GLUE Profitability
Good
  • Gross margin ↑ 100.00%
  • EPS margin↑ 11.50%
  • ROIC↓ 9.80%
Monte Rosa Therapeutics net debt vs free cash flow
GLUE Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Monte Rosa Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗